Emergent BioSolutions (EBS) Total Liabilities (2010 - 2026)

Emergent BioSolutions' Total Liabilities history runs 17 years deep, the most recent figure standing at $797.3 million for Q1 2026.

• On a quarterly basis, Total Liabilities fell 8.71% year-over-year to $797.3 million in Q1 2026; TTM through Mar 2026 was $797.3 million, a 8.71% decrease from a year earlier, with the FY2025 full-year figure at $796.0 million, down 12.23% from the prior year.
• Total Liabilities held at $797.3 million in Q1 2026 per EBS's latest filing, from $796.0 million in the prior quarter.
• Across five years, Total Liabilities topped out at $1.8 billion in Q4 2022 and bottomed at $796.0 million in Q4 2025.
• The 5-year median for Total Liabilities is $1.1 billion (2024), against an average of $1.1 billion.
• Across the five-year window, Total Liabilities jumped 44.98% in 2023 and plunged 34.77% in 2024, its largest moves.
• Year by year, Total Liabilities stood at $1.8 billion in 2022, then slumped by 34.0% to $1.2 billion in 2023, then retreated by 22.74% to $906.9 million in 2024, then fell by 12.23% to $796.0 million in 2025, then advanced by 0.16% to $797.3 million in 2026.
• Per Business Quant, the three latest EBS Total Liabilities figures stand at $797.3 million (Q1 2026), $796.0 million (Q4 2025), and $878.5 million (Q3 2025).